Our pipeline is focused on disease-modifying treatments for tau-related frontotemporal dementia (FTD-tau) and progressive supranuclear palsy (PSP).  TauC3 Biologics’ most advanced candidate in development, TBL-100,  is a humanized monoclonal antibody that uniquely targets the most noxious form of tau, which is slightly shorter and known as tauC3. TBL-100 has the potential to slow down or arrest disease progression with demonstrated evidence of target engagement and activity in preclinical models. 

The company has additionally developed diagnostic tools based on the high specificity and potency of TBL-100 which could be used as a companion diagnostic (CDx), for example to facilitate patient selection and monitor treatment effects.  These tools may also have broader application as a diagnostic (Dx) to distinguish between various neurodegenerative diseases.  

TBL-100 = humanized tauC3-specific mAb; SAD = single ascending dose study (in healthy volunteers); MAD = multiple ascending dose study (in subjects with PSP/FTD-tau); CDx = Companion Diagnostic; Dx =  Diagnostic tool